Cargando…
Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung
Squamous cell and adenocarcinomas of the lung develop different mechanisms during carcinogenesis to evade attacks of the immune system. Besides the well-known check-point control programmed death 1 and its ligand, many more mechanisms, acting either tumoricidal or in favor of tumor progression, exis...
Autores principales: | Brcic, Luka, Stanzer, Stefanie, Krenbek, Dagmar, Gruber-Moesenbacher, Ulrike, Absenger, Gudrun, Quehenberger, Franz, Valipour, Arschang, Lindenmann, Joerg, Stoeger, Herbert, Al Effah, Mohamed, Fediuk, Melanie, Balic, Marija, Popper, Helmut H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924661/ https://www.ncbi.nlm.nih.gov/pubmed/29520483 http://dx.doi.org/10.1007/s00428-018-2326-0 |
Ejemplares similares
-
Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition
por: Tiran, Verena, et al.
Publicado: (2017) -
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
por: Illini, Oliver, et al.
Publicado: (2022) -
Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021) -
Myopericytoma arising from myopericytosis—a hitherto unrecognized entity within the lung
por: Gruber-Moesenbacher, Ulrike, et al.
Publicado: (2020) -
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)